期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Dysregulation of mTOR activity through LKB1 inactivation 被引量:4
1
作者 Wei Zhou Adam I. m arcus paula m. vertino 《Chinese Journal of Cancer》 SCIE CAS CSCD 2013年第8期427-433,共7页
Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal... Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either due to the genetic activation of its upstream activating signaling pathways or the genetic inactivation of its negative regulators. The tumor suppressor liver kinase B1 (LKB1), also known as serine/threonine kinase 11 (STK11), is involved in cell polarity, cell detachment and adhesion, tumor metastasis, and energetic stress response. A key role of LKB1 is to negatively regulate the activity of mTOR complex 1 (mTORC1). This review summarizes the molecular basis of this negative interaction and recent research progress in this area. 展开更多
关键词 MTOR 基因激活 丝氨酸 苏氨酸激酶 失活 失调 活性 信号转导通路 雷帕霉素
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部